Response Assessment in Neuro-Oncology

被引：83

作者：

Quant, Eudocia C. ^{[1
]}

Wen, Patrick Y. ^{[1
]}

机构：

[1] Dana Farber Brigham & Womens Canc Ctr, Dept Med Oncol, Ctr Neurooncol, Boston, MA 02115 USA

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 01期

关键词：

Response criteria; Response assessment; Radiographic response; Macdonald criteria; RANO criteria; High-grade glioma; Low-grade glioma; Meningioma; Brain metastases; Vestibular schwannomas; BEVACIZUMAB PLUS IRINOTECAN; PHASE-II TRIAL; RECURRENT MALIGNANT GLIOMA; BRAIN METASTASES; NEUROFIBROMATOSIS TYPE-2; BREAST-CANCER; CONCOMITANT RADIOCHEMOTHERAPY; DISEASE PROGRESSION; RADIATION-THERAPY; CLINICAL-TRIALS;

D O I：

10.1007/s11912-010-0143-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Accuracy and reproducibility in determining response to therapy and tumor progression can be difficult to achieve for nervous system tumors. Current response criteria vary depending on the pathology and have several limitations. Until recently, the most widely used criteria for gliomas were "Macdonald criteria," based on two-dimensional tumor measurements on neuroimaging studies. However, the Response Assessment in Neuro-Oncology (RANO) Working Group has published new recommendations in high-grade gliomas and is working on recommendations for other nervous system tumors. This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma.

引用

页码：50 / 56

页数：7

共 51 条

[1] Phase 2 Trial of Temozolomide Using Protracted Low-dose and Whole-brain Radiotherapy for Nonsmall Cell Lung Cancer and Breast Cancer Patients With Brain Metastases [J].

Addeo, Raffaele ;

De Rosa, Carmine ;

Faiola, Vincenzo ;

Leo, Luigi ;

Cennamo, Gregorio ;

Montella, Liliana ;

Guarrasi, Rosario ;

Vincenzi, Bruno ;

Caraglia, Michele ;

Del Prete, Salvatore .

CANCER, 2008, 113 (09) :2524-2531

[2]

[Anonymous], 2010, Cancer Facts Figures 2010

[3]

[Anonymous], 2001, Cancer: Principles and Practice of Oncology

[4] Neurofibromatosis type 2 [J].

Asthagiri, Ashok R. ;

Parry, Dilys M. ;

Butman, John A. ;

Kim, H. Jeffrey ;

Tsilou, Ekaterini T. ;

Zhuang, Zhengping ;

Lonser, Russell R. .

LANCET, 2009, 373 (9679) :1974-1986

[5] Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma [J].

Batchelor, Tracy T. ;

Duda, Dan G. ;

di Tomaso, Emmanuelle ;

Ancukiewicz, Marek ;

Plotkin, Scott R. ;

Gerstner, Elizabeth ;

Eichler, April F. ;

Drappatz, Jan ;

Hochberg, Fred H. ;

Benner, Thomas ;

Louis, David N. ;

Cohen, Kenneth S. ;

Chea, Houng ;

Exarhopoulos, Alexis ;

Loeffler, Jay S. ;

Moses, Marsha A. ;

Ivy, Percy ;

Sorensen, A. Gregory ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) :2817-2823

[6] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[7] Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology [J].

Brandes, Alba A. ;

Tosoni, Alicia ;

Spagnolli, Federica ;

Frezza, Giarnpiero ;

Leonardi, Marco ;

Calbucci, Fabio ;

Franceschi, Enrico .

NEURO-ONCOLOGY, 2008, 10 (03) :361-367

[8] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients [J].

Brandes, Alba A. ;

Franceschi, Enrico ;

Tosoni, Alicia ;

Blatt, Valeria ;

Pession, Annalisa ;

Tallini, Giovanni ;

Bertorelle, Roberta ;

Bartolini, Stefania ;

Calbucci, Fabio ;

Andreoli, Alvaro ;

Frezza, Giampiero ;

Leonardi, Marco ;

Spagnolli, Federica ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2192-2197

[9] Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas [J].

Brandsma, Dieto ;

Stalpers, Lukas ;

Taal, Walter ;

Sminia, Peter ;

van den Bent, Martinj .

LANCET ONCOLOGY, 2008, 9 (05) :453-461

[10] STEROID-INDUCED CT CHANGES IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA [J].

CAIRNCROSS, JG ;

MACDONALD, DR ;

PEXMAN, JHW ;

IVES, FJ .

NEUROLOGY, 1988, 38 (05) :724-726

← 1 2 3 4 5 6 →